Daiichi Sankyo to Leverage Ranbaxy's Presence in Mexico for Marketing and Distribution
New Division will bring Daiichi Sankyo's innovator products to Mexican market
Tokyo Japan and Gurgaon India, October
5, 2009, - Daiichi Sankyo Company Limited ("Daiichi
Sankyo") and Ranbaxy Laboratories Limited ("Ranbaxy") announced
today that the portfolio of Daiichi Sankyo would be commercialized
in Mexico through a recently created marketing Division within
Ranbaxy Mexico S.A. de C.V., a subsidiary of Ranbaxy. This is the
first time in Latin America that Daiichi Sankyo and Ranbaxy are
leveraging mutual synergies generated through the Hybrid Business
Model.
Remarking on the development, Mr. Takashi Shoda, President &
CEO of Daiichi Sankyo, said, "We are dedicated to realize
various synergies through our hybrid business model which enables
both companies to fully realize their strengths. I am pleased to
announce one of such synergy, our commitment to directly introduce
Daiichi Sankyo products in Mexico leveraging Ranbaxy's strong
platform. I believe our products will offer an excellent therapy
option to the doctors and patients in Mexico."
Commenting on the occasion, Mr. Atul Sobti, CEO and Managing
Director of Ranbaxy, said, "The creation of a Daiichi Sankyo
Division within Ranbaxy - Mexico marks our first endeavour in
creating a dedicated marketing arm for Daiichi Sankyo's portfolio
of innovator products. Our understanding of Latin American markets
and local presence pave the way for an efficient and immediate
market entry for Daiichi Sankyo, while priming the channel for the
launch of Ranbaxy speciality products in the future."
This hybrid model will enable the two companies to leverage their
respective strengths in the dominant prescription segment, through
the newly created Division, while continuing expansion in the
rapidly evolving Generics market.
With an estimated population of 107 million people, Mexico is Latin
America's second biggest market after Brazil. The annual
pharmaceutical market in Mexico is about USD 10.4 billion and is
ranked the 11th largest in the World.
Ranbaxy Mexico S.A de C.V. has a strong portfolio of generics and
its products are available at leading generic customers and large
Pharmacy chains. Additionally, it has licensing arrangements with
leading Multinational companies.
About Daiichi Sankyo Company, Limited
A global pharma innovator, Daiichi Sankyo Company, Ltd., was
established in 2005 through the merger of two leading Japanese
pharmaceutical companies. This integration created a more robust
organization that allows for continuous development of novel drugs
that enrich the quality of life for patients around the world. A
central focus of Daiichi Sankyo's research and development are
thrombotic disorders, malignant neoplasm, diabetes mellitus, and
autoimmune disorders. Equally important to the company are
hypertension, hyperlipidemia or atherosclerosis and bacterial
infections. For more information, visit
www.daiichisankyo.com.
About Ranbaxy Laboratories Limited
Ranbaxy Laboratories Limited, India's largest pharmaceutical
company, is an integrated, research based, international
pharmaceutical company producing a wide range of quality,
affordable generic medicines, trusted by healthcare professionals
and patients across geographies. Ranbaxy's continued focus on
R&D has resulted in several approvals in developed markets and
significant progress in New Drug Discovery Research. The Company's
foray into Novel Drug Delivery Systems has led to proprietary
"platform technologies," resulting in a number of products under
development. The Company is serving its customers in over 125
countries and has an expanding international portfolio of
affiliates, joint ventures and alliances, ground operations in 49
countries and manufacturing operations in 11 countries.
Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and Representative
Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock
Exchanges)
Please address inquiries to Toshiaki Sai, General Manager,
Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/
Posted: October 2009
